CRBU Q2 2025 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CRBUCaribou Biosciences, Inc.

$186M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-23.0% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$48M-1784.0% margin

Net Income

-$54M-2028.4% margin

EPS (Diluted)

$-0.58

QoQ Revenue Growth

+13.3%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$29M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$221M

Total Liabilities

$55M

Stockholders' Equity

$166M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$3M	-23.0%
Gross Profit	$3M	$3M	+2.3%
Operating Income	-$48M	-$44M	-9.4%
Net Income	-$54M	-$38M	-43.5%

Revenue Segments

Reportable Segment

$3M100%

Geographic Segments

UNITED STATES

$2M62%

Non-US

$1M38%